These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Report of a clinical trial of a Canadian preparation of antihemophilic factor.
    Author: Magnin AA, Johnson SE.
    Journal: Can Med Assoc J; 1979 Aug 18; 121(4):422-4, 427. PubMed ID: 466616.
    Abstract:
    A clinical trial of a Canadian preparation of antihemophilic factor has been completed. The mean percentage increase in the factor VIII coagulant activity in the plasma was determined to be 2.1 +/- 0.8 per unit per kilogram dose, which compares very favourably with published data. The mean half-life of antihemophilic factor was found to be 14.7 hours. Side effects and reactions to the product were minimal and the product has been rated as clinically effective. No significant differences between lots were noted in the in vivo response or the half-life.
    [Abstract] [Full Text] [Related] [New Search]